Heterogeneous point mutations of the p53 gene in pulmonary fibrosis.

Lung cancer is a frequent complication in pulmonary fibrosis. Overexpression of p53 proteins has been demonstrated by immunostaining in bronchoepithelial cells in patients with idiopathic pulmonary fibrosis. However, it is still unclear whether this overexpressed p53 protein is wild-type or mutant. It was hypothesized that pulmonary fibrosis may be a precancerous lesion with deoxyribonucleic acid point mutations in bronchoepithelial cells. Mutations of the p53 gene were tested for by fluorescence-based single-strand conformation polymorphism (FSSCP), cloning-sequencing and immunostaining techniques. Out of 10 tissue samples that demonstrated overexpression of p53 protein by immunostaining, nine (90%) exhibited point mutations and eight (80%) exhibited heterogeneous point mutations of the p53 gene. The mutations found in pulmonary fibrosis were scattered throughout the central part of the p53 gene, and both guanine (G):cytosine (C) to adenine (A):thymine (T) and A:T to G:C transitions were frequently observed. In conclusion, frequent heterogeneous point mutations of the p53 gene were detected in pulmonary fibrosis. These mutations may have resulted from several types of deoxyribonucleic acid damage that occurred in bronchoepithelial cells and this may explain previous findings of a very high incidence of lung cancer complicating pulmonary fibrosis.

[1]  K. Kuwano,et al.  P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. , 1996, American journal of respiratory and critical care medicine.

[2]  Y. Mizushima,et al.  Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. , 1995, Chest.

[3]  D. Carson,et al.  Cancer progression and p53 , 1995, The Lancet.

[4]  M. Kinoshita,et al.  A sensitive and high-resolution method for the detection of mutations in the p53 gene using fluorescence-based PCR-SSCP , 1995 .

[5]  M. Furihata,et al.  The aberrant p53 protein (review). , 1995, International Journal of Oncology.

[6]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[7]  F. Bosch,et al.  Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. , 1993, Cancer research.

[8]  B. Darras,et al.  Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. , 1993, American journal of human genetics.

[9]  U. Pastorino,et al.  Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. , 1992, Cancer research.

[10]  P. Ganly,et al.  p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. , 1992, Oncogene.

[11]  R. Metcalf,et al.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.

[12]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[13]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[14]  T. Kunkel,et al.  Fidelity of DNA synthesis by the Thermus aquaticus DNA polymerase. , 1988, Biochemistry.